Johnson & Johnson

Jones has been hired as senior vice president, senior business development officer at Generations Bank of Rogers. read more >

In Arkansas, all the towns and counties pooled their money by creating the Arkansas Opioid Recovery Partnership. read more >

Doctors and other experts say the problem could persist through the winter cold-and-flu season but should not last as long as other recent shortages of baby formula or prescription drugs. read more >

The pharmacies were accused of contributing to the oversupply of prescription opioids in the state. read more >

The Fayetteville-based company helps major retail brands automate identifying the source of fines the companies impose on suppliers. read more >

The money from Johnson & Johnson, AmerisourceBergen, Cardinal Health and McKesson will begin flowing to communities in April. read more >

The drug maker is submitting early results of a booster study in 10,000 people to make its case. read more >

Arkansas will receive $5.4 million from the multi-state settlement between attorneys general from 47 states, the District of Columbia and five U.S. territories and McKinsey & Co. one of the world's biggest consulting firms. read more >

Following the money explains the opioid crisis and explains why it has been allowed to continue. read more >

Arkansas officials filed a lawsuit against three drug manufacturers Thursday, claiming overzealous and deceptive marketing contributed to an increase in opioid abuse that fueled a spike in overdose deaths. read more >

President Donald Trump on Tuesday ripped into the four business leaders who resigned from his White House jobs panel — the latest sign that corporate America's romance with Trump is faltering — after his equivocal response to violence by white supremacists in Charlottesville, Virginia. read more >

Arkansas Attorney General Dustin McDaniel asked the state Supreme Court on Monday to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson, saying justices did "significant harm" to the state and broke from 170 years of precedent. read more >

The Arkansas Supreme Court on Thursday overturned a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging the drugmaker's marketing of the antipsychotic drug Risperdal. read more >

A lawyer for two pharmaceutical companies argued Thursday that the Arkansas Supreme Court should reverse a $1.2 billion judgment because the trial judge improperly applied a law in the state's lawsuit over improper marketing of the antipsychotic drug Risperdal. read more >